Study on the Relation between Changes of IL-2, TNF-αin Serum in Patients with Chronic Hepatitis B and Action of Treatment with Foscarnet

To investigate the relationships between the changes of Interleukin-2 (IL-2), Tumor necrosis factor (TNF-α) in serum and antiviral action of Foscarnet in patients with chronic hepatitis B(CHB) and the immunoreg-ulation of PFA. Methods: A series of serum samples from 30 patients of chronic hepatitis B were analyzed about alterations in serum quantification of HBV DNA, the levels of IL-2 and TNF-α before, during and after Foscarnet treatment. The serum HBV DNA concentrations were tested by the Fluorescence quantitative PCR (FQ-PCR). The levels of IL-2 and TNF-α were tested by RLA. Results: The experimental date showed that there were 14 patients whose HBV DNA, HBeAg became negative after treatment among the 30 samples (46.7%). It was called response group. The others (16) had not changed (53. 3%). That was the nonresponse group. The average levels of the HBV DNA quantification respectively were 4.52±1. 14、3. 40±1. 20、0 QTY/μl (logarithm) in the response group, and 4. 43±1.29、4. 12±1.02、 3. 83±1. 06QTY/μl (logarithm) in the nonresponse group before during and after treatment. The levels of IL-2, TNF-α both were higher than the normal in the two groups before treatment (P0. 05). In the process of PFA treatment, the levels of IL-2 and TNF-α were elevated in the response group (P0. 05), and decreased in the nonresponse group. But there was not difference after statistics analysis. Conclusion: The results suggested that Foscarnet can pronouncedly inhibit the replication of HBV, but it did not play a role in the body's immunoregulation in short-term.